S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:IMGN

ImmunoGen Stock Forecast, Price & News

$6.62
-0.54 (-7.54%)
(As of 12/3/2021 04:00 PM ET)
Add
Compare
Today's Range
$6.58
$7.12
50-Day Range
$4.75
$7.16
52-Week Range
$4.72
$10.88
Volume
8.08 million shs
Average Volume
7.61 million shs
Market Capitalization
$1.34 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.24
30 days | 90 days | 365 days | Advanced Chart
Receive IMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter.


ImmunoGen logo

About ImmunoGen

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.

Headlines

ImmunoGen (NASDAQ:IMGN) Trading 6.8% Higher
December 2, 2021 |  americanbankingnews.com
-$0.18 EPS Expected for ImmunoGen, Inc. (NASDAQ:IMGN) This Quarter
December 1, 2021 |  americanbankingnews.com
Jefferies Financial Group Upgrades ImmunoGen (NASDAQ:IMGN) to Buy
December 1, 2021 |  americanbankingnews.com
Why ImmunoGen Stock Soared Today
November 30, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:IMGN
CUSIP
45253H10
Employees
79
Year Founded
1981

Sales & Book Value

Annual Sales
$132.30 million
Book Value
$0.38 per share

Profitability

Net Income
$-44.37 million
Pretax Margin
-55.41%

Debt

Price-To-Earnings

Miscellaneous

Free Float
196,358,000
Market Cap
$1.34 billion
Optionable
Optionable

Company Calendar

Last Earnings
10/29/2021
Today
12/04/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/11/2022

Social Links


MarketRank

Overall MarketRank

1.88 out of 5 stars

Medical Sector

757th out of 1,388 stocks

Pharmaceutical Preparations Industry

358th out of 668 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












ImmunoGen (NASDAQ:IMGN) Frequently Asked Questions

Is ImmunoGen a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ImmunoGen stock.
View analyst ratings for ImmunoGen
or view top-rated stocks.

How has ImmunoGen's stock been impacted by Coronavirus?

ImmunoGen's stock was trading at $3.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IMGN stock has increased by 96.4% and is now trading at $6.62.
View which stocks have been most impacted by COVID-19
.

Are investors shorting ImmunoGen?

ImmunoGen saw a decline in short interest in November. As of November 15th, there was short interest totaling 10,430,000 shares, a decline of 35.6% from the October 31st total of 16,200,000 shares. Based on an average daily volume of 1,550,000 shares, the short-interest ratio is presently 6.7 days. Currently, 5.6% of the shares of the company are short sold.
View ImmunoGen's Short Interest
.

When is ImmunoGen's next earnings date?

ImmunoGen is scheduled to release its next quarterly earnings announcement on Friday, February 11th 2022.
View our earnings forecast for ImmunoGen
.

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) released its quarterly earnings results on Friday, October, 29th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.01. The biotechnology company earned $9.20 million during the quarter, compared to the consensus estimate of $19.03 million. ImmunoGen had a negative net margin of 55.41% and a negative trailing twelve-month return on equity of 85.94%. The firm's revenue was down 49.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.13) earnings per share.
View ImmunoGen's earnings history
.

What guidance has ImmunoGen issued on next quarter's earnings?

ImmunoGen issued an update on its FY 2021 earnings guidance on Friday, November, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $65 million-$75 million, compared to the consensus revenue estimate of $70.61 million.

What price target have analysts set for IMGN?

6 brokerages have issued 1-year target prices for ImmunoGen's stock. Their forecasts range from $5.00 to $12.00. On average, they anticipate ImmunoGen's stock price to reach $8.90 in the next year. This suggests a possible upside of 34.4% from the stock's current price.
View analysts' price targets for ImmunoGen
or view top-rated stocks among Wall Street analysts.

Who are ImmunoGen's key executives?

ImmunoGen's management team includes the following people:
  • Mark Joseph Enyedy, President, Chief Executive Officer & Director
  • Susan Altschuller, Chief Financial Officer & Senior Vice President
  • Anna Berkenblit, Chief Medical Officer & Senior Vice President
  • Thomas Ryll, Senior Vice President-Technical Operations
  • Stacy A. Coen, Chief Business Officer & Senior Vice President

What is Mark J. Enyedy's approval rating as ImmunoGen's CEO?

16 employees have rated ImmunoGen CEO Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among ImmunoGen's employees.

What other stocks do shareholders of ImmunoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX).

What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

Who are ImmunoGen's major shareholders?

ImmunoGen's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.59%), Wellington Management Group LLP (6.94%), Morgan Stanley (1.86%), Geode Capital Management LLC (1.69%), Lombard Odier Asset Management Switzerland SA (1.49%) and Candriam Luxembourg S.C.A. (1.26%). Company insiders that own ImmunoGen stock include Craig Barrows, David G Foster, Mark J Enyedy and Thomas Ryll.
View institutional ownership trends for ImmunoGen
.

Which major investors are selling ImmunoGen stock?

IMGN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Healthcare of Ontario Pension Plan Trust Fund, Two Sigma Advisers LP, Two Sigma Investments LP, Wellington Management Group LLP, Morgan Stanley, Dimensional Fund Advisors LP, and Citigroup Inc..
View insider buying and selling activity for ImmunoGen
or view top insider-selling stocks.

Which major investors are buying ImmunoGen stock?

IMGN stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Granahan Investment Management Inc. MA, Pura Vida Investments LLC, Lombard Odier Asset Management Switzerland SA, Integral Health Asset Management LLC, M&G Investment Management Ltd., Creative Planning, and AXA S.A..
View insider buying and selling activity for ImmunoGen
or or view top insider-buying stocks.

How do I buy shares of ImmunoGen?

Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmunoGen's stock price today?

One share of IMGN stock can currently be purchased for approximately $6.62.

How much money does ImmunoGen make?

ImmunoGen has a market capitalization of $1.34 billion and generates $132.30 million in revenue each year. The biotechnology company earns $-44.37 million in net income (profit) each year or ($0.34) on an earnings per share basis.

How many employees does ImmunoGen have?

ImmunoGen employs 79 workers across the globe.

Does ImmunoGen have any subsidiaries?

The following companies are subsidiares of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..

When was ImmunoGen founded?

ImmunoGen was founded in 1981.

What is ImmunoGen's official website?

The official website for ImmunoGen is www.immunogen.com.

Where are ImmunoGen's headquarters?

ImmunoGen is headquartered at 830 WINTER ST, WALTHAM MA, 02451.

How can I contact ImmunoGen?

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at (781) 895-0600, via email at [email protected], or via fax at 781-895-0611.


This page was last updated on 12/4/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.